GlassScriptPhysician profile
Emmanuel A Agaba
NPI 1851698633
$5,140.20
in general payments reported to CMS, 2019-2025
27 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,813 · 2020: $24.99 · 2021: $126 · 2022: $1,517 · 2023: $1,252 · 2024: $288 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183 · Travel and Lodging: $358 · Gift: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.45 |
| Travel and Lodging | $357.99 |
| Gift | $117.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,033.18 | 2022-2023 | Da Vinci Surgical System |
| Medical Device Business Services, INC. | $1,279.85 | 2019 | |
| Ethicon US, LLC | $321.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $210.48 | 2021-2025 | Bridion, Vaxneuvance, Gardasil 9 |
| Medtronic, INC. | $167.71 | 2022 | |
| W. L. Gore & Associates, INC. | $160.08 | 2019-2023 | Gore Enform Preperitoneal Biomaterial |
| Levita Magnetics International Corp | $127.18 | 2019 | |
| Genzyme Corporation | $125.00 | 2024 | |
| Baxter Healthcare | $94.73 | 2023-2024 | Tisseel, Floseal, Seprafilm |
| Takeda Pharmaceuticals U.S.A., INC. | $88.60 | 2022-2024 | Gattex |
| Abbvie INC. | $76.40 | 2023-2025 | Strattice Reconstructive Tissue Matrix Bps |
| Heron Therapeutics, INC. | $67.11 | 2021-2023 | Zynrelef |
| Novo Nordisk INC | $59.33 | 2022-2023 | Rybelsus, Ozempic |
| Davol INC. | $57.04 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.98 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $32.83 | 2019 | |
| Becton, Dickinson and Company | $31.00 | 2023 | Arista Ah Flexitip |
| Innocoll Pharmaceuticals Limited | $26.85 | 2022 | |
| La Jolla Pharmaceutical Company | $23.35 | 2023 | Xerava |
| Integra Lifesciences Corporation | $20.64 | 2024 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Janssen Biotech, INC. | $17.80 | 2025 | Simponi, Simponi Aria, Stelara |
| Smith+Nephew, INC. | $17.66 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.39 | 2022 | |
| Boston Scientific Corporation | $14.02 | 2021 | |
| Daiichi Sankyo INC. | $11.36 | 2020 | |
| Phathom Pharmaceuticals, INC. | $11.16 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Agaba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.